Usefulness of Failed Electrical Cardioversion for Early Recurrence After Catheter Ablation for Atrial Fibrillation as a Predictor of Future Recurrence.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 03 2019
Historique:
received: 11 10 2018
revised: 21 11 2018
accepted: 26 11 2018
pubmed: 19 12 2018
medline: 18 12 2019
entrez: 19 12 2018
Statut: ppublish

Résumé

Early recurrence of atrial arrhythmia (ERAA) during a blanking period after catheter ablation (CA) for atrial fibrillation (AF) does not always result in subsequent AF recurrence. We investigated whether failed electrical cardioversion (ECV) during the blanking period was associated with recurrence. A total of 1,240 consecutive patients who underwent first-time CA for AF at our institution between March 2012 and March 2016 were investigated. Among the 517 patients (42%) who experienced ERAA, 262 underwent ECV. Failure or success of ECV was defined according to the current expert consensus statement. Failed ECV was defined as failure to terminate AF and/or relapse into AF within 30 seconds after transient sinus rhythm conversion by ECV with a shock energy of 270 J in this study. Of the patients, 254 (97%) with restored sinus rhythm were included, and 8 who experienced sustained AF afterward and discontinued the rhythm-control strategy were excluded. We divided the 254 patients into the following 2 groups on the basis of failed or successful ECV: failed-ECV (n = 105; at least 1 failed ECV but experienced successful ECV at a later date nevertheless) and successful-ECV (n = 149, no failed ECV) groups. At the median follow-up period of 610 days after CA, the recurrence rate was higher in the failed-ECV group than in the successful-ECV group (76.2% vs 45.6%, log-rank p < 0.001). After adjustment for baseline differences, failed ECV was found to be a significant predictor of recurrence in the multivariate model (p < 0.001). In conclusion, failed ECV for ERAA was an independent predictor of future recurrence.

Identifiants

pubmed: 30558757
pii: S0002-9149(18)32144-1
doi: 10.1016/j.amjcard.2018.11.039
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

794-800

Informations de copyright

Copyright © 2018. Published by Elsevier Inc.

Auteurs

Ryo Nakamaru (R)

Department of Cardiology, Sakurabashi Watanabe Hospital, Osaka, Japan; Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.

Nobuaki Tanaka (N)

Department of Cardiology, Sakurabashi Watanabe Hospital, Osaka, Japan.

Masato Okada (M)

Department of Cardiology, Sakurabashi Watanabe Hospital, Osaka, Japan.

Koji Tanaka (K)

Department of Cardiology, Sakurabashi Watanabe Hospital, Osaka, Japan.

Yuichi Ninomiya (Y)

Department of Cardiology, Sakurabashi Watanabe Hospital, Osaka, Japan.

Yuko Hirao (Y)

Department of Cardiology, Sakurabashi Watanabe Hospital, Osaka, Japan.

Takafumi Oka (T)

Department of Cardiology, Sakurabashi Watanabe Hospital, Osaka, Japan.

Hiroyuki Inoue (H)

Department of Cardiology, Sakurabashi Watanabe Hospital, Osaka, Japan.

Yasushi Koyama (Y)

Department of Cardiology, Sakurabashi Watanabe Hospital, Osaka, Japan.

Atsunori Okamura (A)

Department of Cardiology, Sakurabashi Watanabe Hospital, Osaka, Japan.

Katsuomi Iwakura (K)

Department of Cardiology, Sakurabashi Watanabe Hospital, Osaka, Japan.

Hiromi Rakugi (H)

Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.

Yasushi Sakata (Y)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.

Kenshi Fujii (K)

Department of Cardiology, Sakurabashi Watanabe Hospital, Osaka, Japan.

Koichi Inoue (K)

Department of Cardiology, Sakurabashi Watanabe Hospital, Osaka, Japan. Electronic address: koichi@inoue.name.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH